Objective: To evaluate the efficacy and safety of sorafenib in Chinese patients with advanced renal cell carcinoma.
Methods: The data of 174 advanced renal cell carcinoma patients orally taking sorafenib in our single center from October 2006 to October 2013 was retrospectively collected. Progression free survival (PFS), overall survival (OS) of these patients and drug-related side effects were analyzed.
Results: Disease control rate was 92% for the whole group. The median PFS of patients taking standard dose (400 mg bid) was (8.0±0.6) months, the median PFS of patients taking increased dose (600 mg bid) after progression was (5.0±1.0) months, the median PFS of patients taking increased dose (800 mg bid) after second-progression was (2.0±0.4) months. The median OS was (24.0±2.8) months. The common side effects included hand-foot reaction (70%), fatigue (57.4%), diarrhea (45.2%), rash (39.9%) and hypertension (21.8%).
Conclusions: Sorafenib has good efficacy and safety in Chinese patients with advanced renal cell carcinoma. Increased dose could bring clinical benefit after standard dose failed.